View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
November 1, 2021

Talaris begins Phase II clinical trial of allogeneic cell therapy

Northwestern University has been selected as the first clinical site and Talaris has started screening eligible patients.

Talaris Therapeutics has commenced its Phase II FREEDOM-2 clinical trial of investigational allogeneic cell therapy, FCR001, in delayed tolerance induction.

This single-arm, multicentre, open-label trial will assess the safety and efficacy of the company’s cell therapy to induce durable immune tolerance in subjects who have received a kidney transplant from a living donor.

This process is known as delayed tolerance induction.

FCR001 is developed to induce or restore immune tolerance in immune-mediated or blood disorder patients who receive organ transplantation.

The US Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation to the therapy.

Talaris Therapeutics chief medical officer Nancy Krieger said: “This trial exploring the efficacy of FCR001 in the delayed tolerance setting is an important step toward potentially offering an alternative to long-term immunosuppression as the standard of care for organ transplant recipients today.

“We believe that this innovative approach could allow us to broaden the opportunity to apply this novel therapy in larger patient populations by expanding the options for previously transplanted patients whose donor is still available.”

In the clinical trial, the patients will be given FCR001 once with non-myeloablative conditioning and followed for five years. A primary analysis of the patients will be performed at 24 months.

The company selected Northwestern University as the first clinical site and the screening for eligible patients has started.

Additional sites for the FREEDOM-2 clinical trial are also anticipated to be activated next year.

Northwestern University Feinberg School of Medicine Fowler McCormick professor of surgery Joseph Leventhal said: “As a physician, I believe the possibility of inducing immune tolerance to a previously-transplanted organ would be transformative.”

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena